Calgary, Canada

Eldon R Smith

This inventor holds 2 USPTO granted patents. Top assignee: Vasogen Ireland Limited. Active years: 2003-2006.


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 24(Granted Patents)


Company Filing History:


Years Active: 2003-2006

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Heart Failure Treatment by Eldon R Smith

Introduction

Eldon R Smith is a notable inventor based in Calgary, Canada. He has made significant contributions to the field of medical treatments, particularly in addressing congestive heart failure (CHF). With a total of 2 patents, his work focuses on innovative methods that enhance patient care.

Latest Patents

Smith's latest patents revolve around a method of treating congestive heart failure in human patients. This method involves treating an aliquot of the patient's blood ex vivo with at least one stressor, which can include a temperature above or below body temperature, an electromagnetic emission, and an oxidative environment. Following this treatment, the aliquot of blood is administered back to the patient. This innovative approach can be utilized independently or as an adjunctive therapy alongside conventional CHF treatments.

Career Highlights

Eldon R Smith has been associated with Vasogen Ireland Limited, where he has contributed to the development of advanced medical therapies. His work has been instrumental in exploring new avenues for treating heart conditions, showcasing his commitment to improving patient outcomes.

Collaborations

Smith collaborates with Guillermo Torre-Amione, a fellow professional in the medical field. Their partnership emphasizes the importance of teamwork in advancing medical innovations.

Conclusion

Eldon R Smith's contributions to the treatment of congestive heart failure highlight his innovative spirit and dedication to improving healthcare. His patents represent a significant step forward in medical technology, offering new hope for patients suffering from this condition.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…